Equillium Stock Price, News & Analysis

Equillium, Inc. (Nasdaq: EQ) announced a presentation at the 3rd Annual Cytokine-Based Drug Development Summit, showcasing its multi-cytokine inhibitor technology. Dr. Stephen Connelly presented data on EQ101, a tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15, which has shown promise in treating inflammatory and neoplastic skin diseases. The company plans to initiate Phase 2 and Phase 1 studies for EQ101 and EQ102, respectively, by year's end. This innovative approach may allow for more selective targeting of cytokines compared to traditional JAK inhibitors.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at Fontainebleau Miami Beach Hotel, and at the Jefferies Healthcare Conference on June 8, 2022, at Marriott Marquis, New York City. The company aims to provide updates on its clinical programs and will hold one-on-one meetings. Both presentations will be accessible via webcast, with archived replays available for 90 days. Equillium is focused on developing therapeutics for severe autoimmune disorders.

Equillium, Inc. (Nasdaq: EQ) has initiated the Phase 3 EQUATOR study of itolizumab for first-line acute graft-versus-host disease (aGVHD). The study aims to enroll up to 200 patients, assessing itolizumab's efficacy against a placebo. Equillium also acquired Bioniz Therapeutics, adding two first-in-class assets to its pipeline. First quarter 2022 financial results showed a net loss of $37.4 million or $(1.17) per share, up from a $9.0 million loss last year due to increased expenses. Cash and equivalents totaled $68.8 million as of March 31, 2022.

Equillium, Inc. (NASDAQ: EQ) announced that the European Hematology Association has published an abstract on the pivotal Phase 3 EQUATOR study for itolizumab in treating acute graft-versus-host disease (aGVHD). The EQUATOR study is a randomized, double-blind trial involving up to 200 patients, comparing itolizumab with placebo alongside corticosteroids. This study aims to address the lack of approved first-line treatments for aGVHD, with outcomes including complete response rates and safety data. The study follows encouraging results from the Phase 1b EQUATE study.

Equillium (Nasdaq: EQ) presented new data on its lead drug, itolizumab, at the IMMUNOLOGY2022 conference. The findings suggest that itolizumab effectively reduces CD6 levels on T effector cells, promoting the development of T regulatory cells, which could enhance treatment strategies for autoimmune diseases. The data indicates that targeting the CD6-ALCAM pathway can prevent harmful T cell recruitment into inflamed organs. Currently in Phase 3 trials for acute graft-versus-host disease, itolizumab shows promise for addressing significant unmet medical needs in immunology.

Equillium, Inc. presented promising data on itolizumab for treating acute graft-versus-host disease (aGVHD) at the Transplantation & Cellular Meetings. The findings indicate a 52% complete response rate and a 64% overall response at Day 29, with ongoing responses observed over 12 months. The data suggests 73% of responders were able to taper corticosteroids significantly. The study also emphasizes the importance of achieving high serum concentrations of itolizumab early on for maximum efficacy, supporting its progression into a pivotal Phase 3 trial.

Equillium, Inc. (Nasdaq: EQ) announced a presentation at the Italian Society of Experimental Hematology Congress, showcasing data on its monoclonal antibody, itolizumab. The study, involving 95 adult patients treated at Dana-Farber Cancer Institute, highlights itolizumab's effectiveness in inhibiting pathogenic T cell proliferation in acute graft-versus-host disease (aGVHD). The findings support advancing itolizumab into a Phase 3 study for first-line aGVHD treatment. This innovative therapy targets the CD6-ALCAM pathway, vital for T cell modulation.

Equillium, Inc. (Nasdaq: EQ) announced positive topline data from the EQUATE study of itolizumab for acute graft-versus-host disease (aGVHD) and initiated the EQUATOR Phase 3 study. The company also presented interim safety data showing a reduction in proteinuria in lupus patients from the EQUALISE study. Additionally, Equillium acquired Bioniz Therapeutics, enhancing its pipeline with two clinical-stage assets. For 2021, R&D expenses rose to $26.4 million, while the net loss was $39.1 million, which is an increase from $29.8 million in 2020. Cash and equivalents stood at $80.7 million.

Equillium, Inc. (NASDAQ: EQ) presented promising results from its EQUATE study on itolizumab for treating high-risk acute graft-versus-host disease (aGVHD) at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation. Key findings include a 72% overall survival rate at 12 months and significant progression-free survival. At Day 29, 52% of patients achieved a complete response (CR), with 64% overall response rate (ORR). Remarkably, responders reduced corticosteroid use by 73% at Day 29 and 96% at six months, suggesting itolizumab's potential as an effective first-line therapy.